Literatura académica sobre el tema "RHG"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "RHG".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "RHG"
Senthilan, Pingkalai R. y Charlotte Helfrich-Förster. "Rhodopsin 7–The unusual Rhodopsin inDrosophila". PeerJ 4 (6 de septiembre de 2016): e2427. http://dx.doi.org/10.7717/peerj.2427.
Texto completoHolloway, T., C. Voigt, J. Morton, S. N. Spak, A. P. Rutter y J. J. Schauer. "An assessment of atmospheric mercury in the Community Multiscale Air Quality (CMAQ) model". Atmospheric Chemistry and Physics Discussions 12, n.º 1 (23 de enero de 2012): 2131–66. http://dx.doi.org/10.5194/acpd-12-2131-2012.
Texto completoHolloway, T., C. Voigt, J. Morton, S. N. Spak, A. P. Rutter y J. J. Schauer. "An assessment of atmospheric mercury in the Community Multiscale Air Quality (CMAQ) model at an urban site and a rural site in the Great Lakes Region of North America". Atmospheric Chemistry and Physics 12, n.º 15 (7 de agosto de 2012): 7117–33. http://dx.doi.org/10.5194/acp-12-7117-2012.
Texto completoSambo, Paolo, Franco Sannazzaro y Michael R. Evans. "Physical Properties of Ground Fresh Rice Hulls and Sphagnum Peat Used for Greenhouse Root Substrates". HortTechnology 18, n.º 3 (enero de 2008): 384–88. http://dx.doi.org/10.21273/horttech.18.3.384.
Texto completoFan, Zhisong, Yu Su, Long Wang, Yudong Wang, Jing Zuo, Fengling Liu y Da Jiang. "Bone pain associated with rhG-CSF or PEG-rhG-CSF in oncology patients." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e19186-e19186. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e19186.
Texto completoYang, Wenyu, Tianfeng Liu, Xiaojuan Chen, Ye Guo, Ting Li, Benquan Qi, Fang Liu et al. "A single-center, open-label clinical study to evaluate pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte stimulating factor in pediatric patients with acute lymphoblastic leukemia." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e22501-e22501. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22501.
Texto completoTakatani, H., H. Soda, M. Fukuda, M. Watanabe, A. Kinoshita, T. Nakamura y M. Oka. "Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts." Antimicrobial Agents and Chemotherapy 40, n.º 4 (abril de 1996): 988–91. http://dx.doi.org/10.1128/aac.40.4.988.
Texto completoPratiwi, Riyona Desvy, Dian Fitria Agustiyanti, Tri Isyani Tungga Dewi, Nina Herlina, Kartika Sari Dewi, Yuliawati Yuliawati, Aminah Aminah y Asrul Muhamad Fuad. "Bioassay of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) for Neutropenia Treatment in Male Sprague Dawley Rats". Molecular and Cellular Biomedical Sciences 4, n.º 1 (1 de marzo de 2020): 10. http://dx.doi.org/10.21705/mcbs.v4i1.81.
Texto completoAndrews, RG, RA Briddell, GH Knitter, T. Opie, M. Bronsden, D. Myerson, FR Appelbaum y IK McNiece. "In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells". Blood 84, n.º 3 (1 de agosto de 1994): 800–810. http://dx.doi.org/10.1182/blood.v84.3.800.bloodjournal843800.
Texto completoOhsaka, A., S. Kitagawa, S. Sakamoto, Y. Miura, N. Takanashi, F. Takaku y M. Saito. "In vivo activation of human neutrophil functions by administration of recombinant human granulocyte colony-stimulating factor in patients with malignant lymphoma". Blood 74, n.º 8 (1 de diciembre de 1989): 2743–48. http://dx.doi.org/10.1182/blood.v74.8.2743.2743.
Texto completoTesis sobre el tema "RHG"
Lundin, Marika. "Verifiering av adsorption och elueringsmetod för identifiering av RhG-antikroppar". Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-96825.
Texto completoKuniechick, Natasha. "Produção do fator estimulador de colônias de granulócitos humano recombinante (rhG-CSF) em biorreator". Pontifícia Universidade Católica do Rio Grande do Sul, 2013. http://hdl.handle.net/10923/5520.
Texto completoThe granulocyte colony-stimulating factor (G-CSF) is a major hematopoietic cytokine involved in the immune defense against infectious agents, stimulating and regulating the proliferation, survival and differentiation of neutrophils precursor cells in the bone marrow. The G-CSF molecule has a 174 amino acids sequence, with a molecular weight of approximately 18. 8 kDa. As a strategy for neutropenia prevention, G-CSF (or filgrastim) has been successfully used in cancer patients whose treatment requires high doses of chemotherapy, in both adults and children. Moreover, this biopharmaceutical may be used to strengthen the immune system in patients with HIV, pneumonia, infections resulting from diabetes, leukemia and febrile neutropenia. Currently, filgrastim is not produced in Brazil, which obligates the government to import this medicine. Due to its wide clinical application, the large scale production of G-CSF is required to supply the demand of national market. In this work, a protocol to obtain this protein was developed using overexpression and cultivation in a bioreactor, solubilization and purification of recombinant G-CSF. The protein was expressed in Escherichia coli host cells C41(DE3) cultures grown in bioreactor using a fed-batch strategy. The expression of the recombinant protein was induced by IPTG. A linear ascending feeding strategy permitted high plasmid stability, low accumulation of acetate in the culture medium, a biomass of approximately 31 g/ L and high expression levels of the protein in the form of inclusion bodies which were solubilized using 2 M urea and alkaline pH. The recombinant protein was purified and yielded approximately 1. 22 mg of homogeneous recombinant protein per gram of wet cells, corresponding to a volumetric yield of 151. 5 mg of rhG-CSF per liter of culture medium. A mass spectrometry analysis was performed, confirming the identity of the recombinant protein. Our work shows a simple and effective strategy to obtain recombinant hG-CSF, stimulating and encouraging a future production of a national biosimilar.
O fator estimulador de colônias de granulócitos (G-CSF) é uma das principais citocinas hematopoiéticas envolvidas na defesa do sistema imune contra agentes infecciosos, estimulando e regulando a proliferação, sobrevivência e diferenciação das células precursoras de neutrófilos na medula óssea. É uma molécula que possui uma sequência de 174 aminoácidos, com peso molecular de aproximadamente 18,8 kDa. Como estratégia de prevenção da neutropenia, o G-CSF (ou filgrastima) é utilizado clinicamente com sucesso em pacientes com câncer, cujo tratamento requer altas doses de quimioterapia, tanto em adultos como em crianças. Além disso, o G-CSF pode ser utilizado para reforçar o sistema imunológico em pacientes com HIV, pneumonia, infecções decorrentes da diabetes, leucemia e neutropenia febril. Atualmente, a filgrastima não é produzida no Brasil, consequentemente, todo medicamento adquirido pelo governo é importado. Tendo em vista sua ampla aplicação clínica, a produção em larga escala do G-CSF se faz necessária para suprir a demanda do mercado nacional e diminuir os custos com importação desse biofármaco. Neste trabalho um protocolo para a produção desta proteína foi desenvolvido, utilizando técnicas de DNA recombinante por meio de experimentos de superexpressão e cultivo em biorreator, solubilização e purificação da G-CSF recombinante. A proteína foi expressa em células Escherichia coli C41(DE3) em cultivos de batelada alimentada em biorreactor, utilizando indução com IPTG e uma estratégia de alimentação linear ascendente, que nos permitiu obter um alto percentual de estabilidade plasmidial, baixo acúmulo de acetato no meio de cultivo, uma biomassa de aproximadamente 31 g/ L e elevados níveis de expressão da proteína em forma de corpos de inclusão, que foram solubilizados utilizando ureia 2 M e pH alcalino. A proteína recombinante foi purificada obtendo-se aproximadamente 1,22 mg de proteína recombinante homogênea por grama de células úmida, correspondendo a um rendimento volumétrico de 151,5 mg de rhG-CSF por litro de meio de cultura. Uma análise por espectrometria de massa também foi realizada, confirmando a identidade da proteína recombinante. Nosso trabalho mostra uma estratégia simples e eficaz para obter hG-CSF recombinante, contribuindo e estimulando a futura produção de um biossimilar nacional.
Gomes, Fernanda Resende. "Expressão do fator estimulador de colônia de granulócito humano recombinante (rhG-CSF) em Escherichia coli". Universidade de São Paulo, 2010. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-13082010-163827/.
Texto completoThe recombinant human granulocyte colony stimulating factor (rhG-CSF) is a non-glycosylated protein with 175 amino acids. This factor plays an important role in hematopoietic cell proliferation and has been widely used for treating neutropenia. The purpose of this work is to construct two expression systems in E. coli; a system for obtaining rhG-CSF in the cytoplasm and the other for secretion of recombinant protein in the culture medium using the signal sequence of L-asparaginase II. The two expression systems were tested and compared. From these data, the next steps for obtaining the rhG-CSF were done with the expression system without the signal sequence. The refolding and purification steps were efficient, resulting in a protein with adequate purity, structural integrity and biological activity. This protein has also been successfully used for the production of polyclonal antibodies in mice. With these results, the protein rhG-CSF was feasible for further studies in bioreactors and pilot scale production.
Carmo, Fillipe Luiz Rosa do. "Clonagem, expressão e caracterização do fator estimulador de colônia de granulócito humano recombinante (rhG-CSF) em Escherichia coli". Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/60/60135/tde-17042015-112052/.
Texto completoThe expression system in Escherichia coli was the first to be used to produce recombinant pharmaceuticals and has many advantages compared to eukaryotic systems, such as easy cultivation and high production potential at low costs. The granulocyte colony (G-CSF) stimulating factor acts primarily by promoting the maturation of neutrophils and stimulating their phagocytic and chemotactic activity. G-CSF is also involved with the process of neutrophils nuclear segmentation. The recombinant human granulocyte colonies stimulating factor (rhG-CSF) has been produced by genetic engineering in Escherichia coli, and it is used to treat of several conditions, especially neutropenia caused by chemotherapy used in the treatment of tumors, by radiotherapy and by the use of drugs that suppress the production of myeloid cells. The present study aimed the expression of rhG-CSF protein in Escherichia coli bacteria. The cloning of rhG-CSF gene in the expression vector pET- 28a (+) was carried out on the restriction sites of the EcoRI and XhoI enzymes. Expression of the recombinant protein in Escherichia coli BL21DE3 was successfully achieved. The rhG-CSF protein, fused with a six histidine tag, was obtained and successfully purified and identified by the Western Blotting and by mass spectrometry techniques. Studies are needed to assess the structural integrity and biological activity of the protein produced, which, if confirmed, enables the production on a pilot scale.
Kuniechick, Natasha. "Produ??o do fator estimulador de col?nias de granul?citos humano recombinante (rhG-CSF) em biorreator". Pontif?cia Universidade Cat?lica do Rio Grande do Sul, 2013. http://tede2.pucrs.br/tede2/handle/tede/5478.
Texto completoThe granulocyte colony-stimulating factor (G-CSF) is a major hematopoietic cytokine involved in the immune defense against infectious agents, stimulating and regulating the proliferation, survival and differentiation of neutrophils precursor cells in the bone marrow. The G-CSF molecule has a 174 amino acids sequence, with a molecular weight of approximately 18.8 kDa. As a strategy for neutropenia prevention, G-CSF (or filgrastim) has been successfully used in cancer patients whose treatment requires high doses of chemotherapy, in both adults and children. Moreover, this biopharmaceutical may be used to strengthen the immune system in patients with HIV, pneumonia, infections resulting from diabetes, leukemia and febrile neutropenia. Currently, filgrastim is not produced in Brazil, which obligates the government to import this medicine. Due to its wide clinical application, the large scale production of G-CSF is required to supply the demand of national market. In this work, a protocol to obtain this protein was developed using overexpression and cultivation in a bioreactor, solubilization and purification of recombinant G-CSF. The protein was expressed in Escherichia coli host cells C41(DE3) cultures grown in bioreactor using a fed-batch strategy. The expression of the recombinant protein was induced by IPTG. A linear ascending feeding strategy permitted high plasmid stability, low accumulation of acetate in the culture medium, a biomass of approximately 31 g/ L and high expression levels of the protein in the form of inclusion bodies which were solubilized using 2 M urea and alkaline pH. The recombinant protein was purified and yielded approximately 1.22 mg of homogeneous recombinant protein per gram of wet cells, corresponding to a volumetric yield of 151.5 mg of rhG-CSF per liter of culture medium. A mass spectrometry analysis was performed, confirming the identity of the recombinant protein. Our work shows a simple and effective strategy to obtain recombinant hG-CSF, stimulating and encouraging a future production of a national biosimilar.
O fator estimulador de col?nias de granul?citos (G-CSF) ? uma das principais citocinas hematopoi?ticas envolvidas na defesa do sistema imune contra agentes infecciosos, estimulando e regulando a prolifera??o, sobreviv?ncia e diferencia??o das c?lulas precursoras de neutr?filos na medula ?ssea. ? uma mol?cula que possui uma sequ?ncia de 174 amino?cidos, com peso molecular de aproximadamente 18,8 kDa. Como estrat?gia de preven??o da neutropenia, o G-CSF (ou filgrastima) ? utilizado clinicamente com sucesso em pacientes com c?ncer, cujo tratamento requer altas doses de quimioterapia, tanto em adultos como em crian?as. Al?m disso, o G-CSF pode ser utilizado para refor?ar o sistema imunol?gico em pacientes com HIV, pneumonia, infec??es decorrentes da diabetes, leucemia e neutropenia febril. Atualmente, a filgrastima n?o ? produzida no Brasil, consequentemente, todo medicamento adquirido pelo governo ? importado. Tendo em vista sua ampla aplica??o cl?nica, a produ??o em larga escala do G-CSF se faz necess?ria para suprir a demanda do mercado nacional e diminuir os custos com importa??o desse biof?rmaco. Neste trabalho um protocolo para a produ??o desta prote?na foi desenvolvido, utilizando t?cnicas de DNA recombinante por meio de experimentos de superexpress?o e cultivo em biorreator, solubiliza??o e purifica??o da G-CSF recombinante. A prote?na foi expressa em c?lulas Escherichia coli C41(DE3) em cultivos de batelada alimentada em biorreactor, utilizando indu??o com IPTG e uma estrat?gia de alimenta??o linear ascendente, que nos permitiu obter um alto percentual de estabilidade plasmidial, baixo ac?mulo de acetato no meio de cultivo, uma biomassa de aproximadamente 31 g/ L e elevados n?veis de express?o da prote?na em forma de corpos de inclus?o, que foram solubilizados utilizando ureia 2 M e pH alcalino. A prote?na recombinante foi purificada obtendo-se aproximadamente 1,22 mg de prote?na recombinante homog?nea por grama de c?lulas ?mida, correspondendo a um rendimento volum?trico de 151,5 mg de rhG-CSF por litro de meio de cultura. Uma an?lise por espectrometria de massa tamb?m foi realizada, confirmando a identidade da prote?na recombinante. Nosso trabalho mostra uma estrat?gia simples e eficaz para obter hG-CSF recombinante, contribuindo e estimulando a futura produ??o de um biossimilar nacional.
Wiik, H. (Heikki). "Inflammatory response following abdominal surgery and its modulation by recombinant human granulocyte colony-stimulating factor (rhG-CSF, filgrastim)". Doctoral thesis, University of Oulu, 2002. http://urn.fi/urn:isbn:9514268474.
Texto completoGranström, Pontus, Lisa Larsson y Oscar Lönnerheden. "”Handboll är ju en så jävla komplex sport” : Kompetenskrav i elithandboll, en jämförelse mellan elitlagstränare och RHG-instruktörer". Thesis, Linnéuniversitetet, Institutionen för idrottsvetenskap (ID), 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-45551.
Texto completoAzevedo, Wellington Morais de. "Transplante alogenico de celulas-tronco perifericas mobilizadas por rhG-CSF, não manipuladas in vitro, para tratamento de neoplasias hematologicas". [s.n.], 1995. http://repositorio.unicamp.br/jspui/handle/REPOSIP/308632.
Texto completoTese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-07-20T17:36:43Z (GMT). No. of bitstreams: 1 Azevedo_WellingtonMoraisde_D.pdf: 3412808 bytes, checksum: 37fe74ea6f2a3b91910127765c8e266e (MD5) Previous issue date: 1995
Resumo: Transplantes autoplásticos de células-tronco periféricas (CTP) já vêm sendo realizados há algum tempo, tendo mostrado algumas vantagens em relação aos transplantes do mesmo tipo que utilizam medula óssea. Dentre estas vantagens, destaca-se a capacidade das CTP de produzir uma "pega" mais rápida do enxerto, encurtando o período de aplasia de medula óssea que se segue ao condicionamento do paciente. A coleta de CTP por aférese oferece maior conforto ao doador, que não precisa ser submetido à anestesia geral e às numerosas punções da crista ilíaca necessárias à obtenção do número de células suficientes para o transplante. Apesar das evidentes vantagens observadas no cenário autoplástico, a aplicação da mesma técnica aos transplantes alogênicos só se iniciou no começo dos anos 90. Este retardo se deveu ao temor de que os enxertos de CTP alogênicas, mais ricos em células T imunocompetentes, pudessem acarretar aumentos na incidência e gravidade da doença do enxerto-contra-o-hospedeiro (DECH). Outro empecilho à realização desses transplantes é a ecessidade de mobilização das CTP para a circulação sangüínea, que se fez possível nos transplantes autoplásticos, inicialmente, pelo uso de quimioterápicos citotóxicos; tal prática seria eticamente condenável em doadores sadios e, só mais recentemente, os fatores de crescimento hematopoiético humanos, obtidos por tecnologia de recombinação gênica (rhGCSF), ofereceram uma alternativa mais segura para conseguir essa mobilização. Neste estudo, não controlado analisamos os resultados de dezessete transplantes alogênios de CTP, comparando-os com aqueles obtidos em um grupo-controle que recebeu, contemporaneamente, transplantes alogênicos convencionais de medula óssea. O objetivo foi o de se estudar, comparativamente, o perfil de "pega" dos enxertos de CTP, assim como a morbidade associada ao procedimento. Para tanto, foram comparados vários parâmetros entre os dois grupos, que incluíram: tempo de "pega" do enxerto, tempo de permanência no hospital após o transplante, necessidade de transfusões, número de dias em uso de antimicrobianos ou nutrição parenteral, níveis séricos máximos de creatinina e bilirrubina, incidência e gravidade de DECH aguda, entre outros. Procuramos avaliar ainda os eventuais efeitos colaterais a curto prazo do rhG-CSF nos doadores. Os resultados mostraram que a incidência e gravidade da DECH aguda foram comparáveis entre os dois grupos, assim como a morbidade geral relacionada ao transplante. De fato, os transplantes com CTP apresentaram "pega" mais rápida e permitiram alta hospitalar mais precoce. A mobilização de CTP pelo uso de rhG-CSF e sua obtenção por sessões únicas de aférese mostraram-se, no período estudado, livres de efeitos colaterais ou complicações clínicas sérias para os doadores. O número de células foi suficiente para garantir a "pega" e estabilidade do enxerto em todos os pacientes, não se observando rejeições ou "falhas de pega". Aparentemente, as vantagens oferecidas pelas CTP em transplantes autoplástiéos também se aplicam aos transplantes alogênicos. Os resultados sugerem ser a técnica viável, porém devem ser interpretados com cautela devido às limitações metodológicas do estudo, que incluem o curto tempo de seguimento dos pacientes e a realização de análise de dados de grupos de pacientes distribuídos sem "randomização"
Abstract: Autologous blood stem celI (BSC) transplantation is already a welI established medical procedure, which has shown some advantages over the use of bone marrow for the same purpose. A faster engraftment rate is observed in these transplants, consequently shortening the period of marrow aplasia that folIows the conditioning phase. Besides, BSC colIection by apheresis offers more cornfort to the donors, avoiding the need for general anesthesia and marrow aspiration in order to obtain sufficient numbers of stem celIs for engraftment. Despite alI these advantages, the use of allogeneic BSC for transplantation did not start until the beginning of the Nineties. The application of the technique had always been hampered by the fear. that BSC grafts, which contain a larger amount of immunocompetent T -celIs, could result in intolerable increases of graft-versus-host disease (GVHD) incidence and severity. ColIection ofBSC by apheresis requires that these celIs first be mobilized to the circulation, a task acomplished initially by the use of antinoeplastic cytotoxic drugs. The administration of such agents to healthy donors would be a clearly unnacceptable practice, and, only Tecently, recombinant human hematopoietic growth factors (rhG-CSF) have offered a reasonable alternative for this purpose. In thi~ study, we retrospectively analyze the results of seventeen allogeneic BSC transplants, comparing them to those obtained in a control group of patients who received conventional allogeneic marrow transplants contemporarily fashion. The objective was to study the engraftment profile of the BSC grafts, as welI as the general transplant-associated morbidity. For this purpose, several parameters were assessed and compared between the two groups, including: time to engraftment, transfusion needs, number of days under antimicrobial treatment and parenteral nutrition, maximal serum levels of creatinine and bilirubin, incidence and severity of acute GVHD, among others. We also analyzed the eventual short-term deleterious effects of rhG-CSF upon donors. The results have pointed to a comparable incidence and severity of acute GVHD in the two populations, as well as similar transplant-associated morbidity profiles. Indeed, BSC grafts produced significantly faster engraftment and shorter hospital stays. Donor stem cell mobilization by rhG-CSF and their collection by single apheresis sessions have been devoid of significant side-effects or clinical complications in the study period. The numbers of cells collected have always proven sufficient to promote good engraftment, with no documentated of rejection or any other kind of graft failure. It seems apparent that the advantages offered by autologous BSC transplants can be shared by their allogeneic counterparts. The results suggest that allogeneic BSC transplantation is a feasible procedure, but one must not forget that this was not a randomized, prospective study, and that our follow-up time was not long enough to permit safe conclusions about the issue. More studies are necessary until we can replace alogeneic BSC transplantation for conventional bone marrow transplants
Doutorado
Clinica Medica
Doutor em Clínica Médica
RONZINO, ANDREA. "Unpacking Robin Hood gardens: the troubled history of a British public housing project (1952) 1963/1972 (2018)". Doctoral thesis, Politecnico di Torino, 2021. http://hdl.handle.net/11583/2914548.
Texto completoKazi, Samreen H. "Minimum tile-derived microsatellite markers improve the physical map of the soybean genome and the Flyer and Hartwig genetic map at Rhg, Rfs and yield loci /". Available to subscribers only, 2005. http://proquest.umi.com/pqdweb?did=1075682461&sid=1&Fmt=2&clientId=1509&RQT=309&VName=PQD.
Texto completo"Department of Molecular Biology, Microbiology and Biochemisty." Includes bibliographical references (leaves 154-176). Also available online.
Libros sobre el tema "RHG"
École nationale supérieure d'architecture de Paris-Belleville, ed. RHG/ENSAPB: [Direction de l'ouvrage, Ginette Baty-Tornikian]. Paris: Éditions Recherches, 2006.
Buscar texto completoLhuiṅʻ, Kraṅʻ. Budha bhu rā ̋ rhaṅʻ sakʻ toʻ thaṅʻ rhā ̋rhi cañʻ kāla n* thaṅʻ rhā ̋ so tanʻ khui ̋ rhaṅʻ myā ̋. (Ranʻ kunʻ): Cā ʼupʻ myā ̋puṃ nhipʻ thut ve re ̋ koʻmatī, ʼA myui ̋ sā ̋ lūʹ cvamʻ ̋ʼa ̋ʼa raṅʻ ̋ʼa mracʻ phvaṃʹ phrui ̋ mhu ṭhāna, Paññʻa re ̋ vanʻ krī ̋ ṭhāna, 2003.
Buscar texto completoCorporation, Gateway Learning, ed. Rag. [Foster City, Calif.]: Gateway Learning Corporation, 1998.
Buscar texto completoBarker, Nicholas. Rig. London: W.H.Allen, 1990.
Buscar texto completoJulie, Carr. Rag. Richmond, California: Omnidawn Publishing, 2014.
Buscar texto completoFishār-i reg: Fishaar-e-reg. Ḥaidarābād: al-Anṣār Pablīkeshanz, 2012.
Buscar texto completoChve, Sanʻʺ. Phve phve rhā rhā samuiṅʻʺ cā. Ranʻ kunʻ: Kaṃʹ koʻ vatʻ raññʻ Cā pe, 2012.
Buscar texto completoKyoʻ, ʼOṅʻ. Tacche ta kayʻ rhi ma rhi. Ranʻ kunʻ: ʼA suiṅʻʺ ʼA vuiṅʻʺ Cā pe, 1997.
Buscar texto completoRtsom rig gśib bsdur rig lam. Pe-cin: Mi rigs dpe skrun khaṅ, 2000.
Buscar texto completoGso rig dang gnam rig skor rtsis. [Lha-sa]: Bod ljongs mi dmangs dpe skrun khang, 2014.
Buscar texto completoCapítulos de libros sobre el tema "RHG"
Drize, N. J., J. L. Chertkov y A. R. Zander. "Combination of rhSCF + rhG-SCF, But Not rhG-CSF Alone Potentiate the Mobilization of Hematopoietic Stem Cells with Increased Repopulating Ability into Peripheral Blood of Mice". En Acute Leukemias V, 391–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-78907-6_66.
Texto completoGross-Weege, W., M. Weiss, M. Wenning, M. Schneider, C. Ohmann y H. Becker. "Phase II-Studie zur Prophylaxe und Therapie der Sepsis bei chirurgischen, intensiv-therapiepflichtigen Patienten mit rhG-CSF". En Chirurgisches Forum ’94, 423–26. Berlin, Heidelberg: Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78905-2_84.
Texto completoAndreeff, M., A. Tafuri y S. Hegewisch-Becker. "Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside". En Acute Leukemias II, 747–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74643-7_137.
Texto completoBauhofer, A., M. Huttel, K. P. Reimund, I. Celik, B. Greger y W. Lorenz. "Wirksame Prophylaxe mit rhG-CSF bei abdomineller Sepsis: Verbesserung antimikrobieller Funktionen von Granulocyten als neuer Mechanismus in vivo". En Chirurgisches Forum ’97 für experimentelle und klinische Forschung, 593–96. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60717-2_119.
Texto completoMoore, M. A. S., K. Welte, J. Gabrilove y L. M. Souza. "Biological Activities of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) and Tumor Necrosis Factor: In Vivo and In Vitro Analysis". En Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, 210–20. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72624-8_45.
Texto completoKröger, N., H. Renges, W. Krüger, K. Gutensohn, C. Löliger, I. Carrero, B. Cortez y A. R. Zander. "A Randomized Comparison of Once Versus Twice Daily rhG-CSF (Filgrastim) for Stem Cell Mobilisation in Healthy Donors for Allogeneic Transplantation". En Transplantation in Hematology and Oncology II, 138–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55774-3_17.
Texto completoGass, Saul I. y Carl M. Harris. "RHS". En Encyclopedia of Operations Research and Management Science, 720. New York, NY: Springer US, 2001. http://dx.doi.org/10.1007/1-4020-0611-x_894.
Texto completoGooch, Jan W. "Rhe". En Encyclopedic Dictionary of Polymers, 631. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-6247-8_10021.
Texto completoZahid, Sarwar, Kari Branham, Dana Schlegel, Mark E. Pennesi, Michel Michaelides, John Heckenlively y Thiran Jayasundera. "RHO". En Retinal Dystrophy Gene Atlas, 215–18. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-10867-4_67.
Texto completoShoff, William H., Catherine T. Shoff, Suzanne M. Shepherd, Jonathan L. Burstein, Calvin A. Brown, Ashita J. Tolwani, Bala Venkatesh et al. "RBG". En Encyclopedia of Intensive Care Medicine, 1955. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_2134.
Texto completoActas de conferencias sobre el tema "RHG"
Huot, N., G. Pauliat, J. M. C. Jonathan, G. Roosen, R. Scharfschwerdt, O. F. Schirmer y D. Rytz. "Four fold improvement of the photorefractive time constant of BaTiO3:Rh by oxidation". En The European Conference on Lasers and Electro-Optics. Washington, D.C.: Optica Publishing Group, 1998. http://dx.doi.org/10.1364/cleo_europe.1998.cfe2.
Texto completoFreudenreich, Klaus. "Rho-rho production in two-photon collisions". En International Europhysics Conference on High Energy Physics. Trieste, Italy: Sissa Medialab, 2007. http://dx.doi.org/10.22323/1.021.0112.
Texto completoCelepcikay, Oner Ulvi y Christoph F. Eick. "REG^2". En the 17th ACM SIGSPATIAL International Conference. New York, New York, USA: ACM Press, 2009. http://dx.doi.org/10.1145/1653771.1653816.
Texto completoBai, Bo (Bob), Wei Chen, Khaled Ben Letaief y Zhigang Cao. "RBG matching". En the 6th International Wireless Communications and Mobile Computing Conference. New York, New York, USA: ACM Press, 2010. http://dx.doi.org/10.1145/1815396.1815540.
Texto completoMarquis Bolduc, Mathieu y Hau Nghiep Phan. "Rig Inversion by Training a Differentiable Rig Function". En SA '22: SIGGRAPH Asia 2022. New York, NY, USA: ACM, 2022. http://dx.doi.org/10.1145/3550340.3564218.
Texto completoVishwakarm, K., M. Chaturvedi, O. Ojo y P. Wanjara. "Linear Friction Welding of Allvac® 718Plus® Superalloy". En Superalloys. John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.7449/2010/superalloys_2010_413_426.
Texto completoAndersson, J., G. Sjöberg y M. Chaturvedi. "Hot Ductility Study of HAYNES® 282® Superalloy". En Superalloys. John Wiley & Sons, Inc., 2010. http://dx.doi.org/10.7449/2010/superalloys_2010_539_554.
Texto completoBiajone, Jefferson, Vitor Emanuel Queiroz Ferreira, Andressa Silvério Terra França, Maylon Pires Macedo y Guilherme Rosa de Moraes. "Fatec RPG: Jogo interativo via RPG Maker VX Ace". En 13th CONTECSI International Conference on Information Systems and Technology Management. TECSI, 2016. http://dx.doi.org/10.5748/9788599693124-13contecsi/pst-1018.
Texto completo"Reg-1: Registration". En 2017 9th IEEE-GCC Conference and Exhibition (GCCCE). IEEE, 2017. http://dx.doi.org/10.1109/ieeegcc.2017.8448042.
Texto completoCosta, Alexandre Monte Alto, Ricardo Tolosa, Sidnei Kameoka y Luis Fernando Caldo. "Rig Tests Optimization". En SAE Brasil 2003 Congress and Exhibit. 400 Commonwealth Drive, Warrendale, PA, United States: SAE International, 2003. http://dx.doi.org/10.4271/2003-01-3693.
Texto completoInformes sobre el tema "RHG"
Falk, A. Comment on Extracting alpha from B to rho rho. Office of Scientific and Technical Information (OSTI), octubre de 2003. http://dx.doi.org/10.2172/826521.
Texto completoBevan, A. Measurements of sin2 alpha phi_2 from B to pi pi, rho pi and rho rho Modes. Office of Scientific and Technical Information (OSTI), noviembre de 2004. http://dx.doi.org/10.2172/839802.
Texto completoMeyer, William R. Rocket Propelled Grenade (RPG), RPG-7VM, MIL-STD-1660 Tests. Fort Belvoir, VA: Defense Technical Information Center, agosto de 1995. http://dx.doi.org/10.21236/ada391649.
Texto completoBoone, S. G. TRU VU rig instrumentation. Office of Scientific and Technical Information (OSTI), febrero de 1993. http://dx.doi.org/10.2172/6745935.
Texto completoRamey, Garey y Valerie Ramey. The Rug Rat Race. Cambridge, MA: National Bureau of Economic Research, agosto de 2009. http://dx.doi.org/10.3386/w15284.
Texto completoSchock, Alfred. Mars Rover RTG Study. Office of Scientific and Technical Information (OSTI), octubre de 1989. http://dx.doi.org/10.2172/1033348.
Texto completoSchock, Alfred. Mars Rover RTG Study. Office of Scientific and Technical Information (OSTI), noviembre de 1989. http://dx.doi.org/10.2172/1033388.
Texto completoSchock, Alfred. Mars Rover RTG Study. Office of Scientific and Technical Information (OSTI), agosto de 1989. http://dx.doi.org/10.2172/1033423.
Texto completoKelly, C. E. y P. M. Klee. Cassini RTG acceptance test results and RTG performance on Galileo and Ulysses. Office of Scientific and Technical Information (OSTI), junio de 1997. http://dx.doi.org/10.2172/481894.
Texto completoAubert, B. Observation of e+e- Annihilations into the C=+1 Hadronic Final States \rho^0\rho^0 and \phi\rho^0. Office of Scientific and Technical Information (OSTI), junio de 2006. http://dx.doi.org/10.2172/885278.
Texto completo